Last reviewed · How we verify
Pancreatic adenocarcinoma — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Pancreatic adenocarcinoma (Pancreatic adenocarcinoma) — Assistance Publique - Hôpitaux de Paris.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Pancreatic adenocarcinoma TARGET | Pancreatic adenocarcinoma | Assistance Publique - Hôpitaux de Paris | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Pancreatic adenocarcinoma CI watch — RSS
- Pancreatic adenocarcinoma CI watch — Atom
- Pancreatic adenocarcinoma CI watch — JSON
- Pancreatic adenocarcinoma alone — RSS
Cite this brief
Drug Landscape (2026). Pancreatic adenocarcinoma — Competitive Intelligence Brief. https://druglandscape.com/ci/pancreatic-adenocarcinoma. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab